2-[5-[1-[3,4-Bis(difluoromethoxy)phenyl]-2-(1-oxidopyridin-1-ium-4-yl)ethyl]-1,3-thiazol-2-yl]propan-2-ol

• 分子结构分类: 有机化合物 - 苯类化合物 - 苯酚醚
• 英文名称: 2-[5-[1-[3,4-Bis(difluoromethoxy)phenyl]-2-(1-oxidopyridin-1-ium-4-yl)ethyl]-1,3-thiazol-2-yl]propan-2-ol
• 化学式: C21H20F4N2O4S
• 分子量: 472.5
• InChiKey: GIAQWCPGSGKMCZ-UHFFFAOYSA-N

计算性质

• 辛醇/水分配系数(LogP)：
  4.2
• 重原子数：
  32
• 可旋转键数：
  9
• 环数：
  3.0
• sp3杂化的碳原子比例：
  0.33
• 拓扑面积：
  105
• 氢给体数：
  1
• 氢受体数：
  10

文献信息

• Combination treatment for depression and anxiety
  申请人：Pfizer Inc.

  公开号：US20040001895A1

  公开（公告）日：2004-01-01

  The present invention relates to a method of treating depression or anxiety in a mammal, including a human, by administering to the mammal a CNS-penetrant NK-1 receptor antagonist (e.g., a substance P receptor antagonist) in combination with a PDE IV inhibitor. It also relates to pharmaceutical compositions containing a pharmaceutically acceptable carrier, a CNS-penetrant NK-1 receptor antagonist and a PDE IV inhibitor.

  本发明涉及一种治疗哺乳动物，包括人类的抑郁症或焦虑症的方法，通过向哺乳动物（例如，人类）施用穿透中枢神经系统的NK-1受体拮抗剂（例如，物质P受体拮抗剂）与PDE IV抑制剂相结合。它还涉及含有药物接受者可接受的载体，穿透中枢神经系统的NK-1受体拮抗剂和PDE IV抑制剂的制药组合物。
• COMBINATIONS OF PDE-V INHIBITORS AND NK1 ANTAGONISTS FOR THE TREATMENT OF DEPRESSION
  申请人：Pfizer Products Inc.

  公开号：EP1515708A1

  公开（公告）日：2005-03-23
• TREATMENT FOR DEPRESSION AND ANXIETY WITH THE COMBINATION OF A PDE IV INHIBITOR AND AN ANTIDEPRESSANT OR AN ANXIOLYTIC AGENT
  申请人：Pfizer Products Inc.

  公开号：EP1517707A1

  公开（公告）日：2005-03-30
• [EN] COMBINATION OF PDE-V INHIBITORS AND NK1 ANTAGONISTS FOR THE TREATMENT OF DEPRESSION<br/>[FR] COMBINAISONS D'INHIBITEURS DE PDE-V ET D'ANTAGONISTES DE NK1 DANS LE TRAITEMENT DE LA DEPRESSION
  申请人：PFIZER PROD INC

  公开号：WO2003105815A1

  公开（公告）日：2003-12-24

  The present invention relates to a method of treating depression or anxiety in a mammal, including a human, by administering to the mammal a CNS-penetrant NK-1 receptor antagonist (e.g., a substance P receptor antagonist) in combination with a PDE IV inhibitor. It also relates to pharmaceutical compositions containing a pharmaceutically acceptable carrier, a CNS-penetrant NK-1 receptor antagonist and a PDE IV inhibitor.
• [EN] TREATMENT FOR DEPRESSION AND ANXIETY BY THE COMBINATION OF A PDE IV INHIBITOR AND AN ANTIDEPRESSANT OR AN ANXIOLYTIC AGENT<br/>[FR] TRAITEMENT DE LA DEPRESSION ET DE L'ANXIETE PAR LA COMBINAISON D'UN INHIBITEUR DE PDE IV ET D'UN ANTIDEPRESSEUR OU AGENT ANXIOLYTIQUE
  申请人：PFIZER PROD INC

  公开号：WO2003105902A1

  公开（公告）日：2003-12-24

  The present invention relates to a method of treating depression or anxiety in a mammal, including a human, by administering to the mammal a PDE IV inhibitor in combination with an antidepressant or an anxiolytic agent. It also relates to pharmaceutical compositions containing a pharmaceutically acceptable carrier, a PDE IV inhibitor and an anxiolytic agent or antidepressant.